LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Bristol-Myers Squibb Co.

Slēgts

SektorsVeselības aprūpe

48.26 0.98

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.11

Max

48.3

Galvenie mērījumi

By Trading Economics

Ienākumi

2.4B

2.5B

Pārdošana

-1.1B

11B

P/E

Sektora vidējais

17.496

53.54

EPS

1.8

Dividenžu ienesīgums

5.29

Peļņas marža

21.98

Darbinieki

34,100

EBITDA

1.9B

4.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+16.05% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

5.29%

2.44%

Nākamie ieņēmumi

2025. g. 31. jūl.

Nākamais dividenžu datums

2025. g. 31. jūl.

Nākamais Ex dividenžu datums

2025. g. 4. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-17B

95B

Iepriekšējā atvēršanas cena

47.28

Iepriekšējā slēgšanas cena

48.26

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Bristol-Myers Squibb Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 11:32 UTC

Peļņas

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

2025. g. 13. maijs 16:48 UTC

Iegādes, apvienošanās, pārņemšana

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

2025. g. 12. maijs 22:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025. g. 12. maijs 18:45 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025. g. 12. maijs 17:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025. g. 12. maijs 12:07 UTC

Tirgus saruna

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025. g. 7. maijs 20:09 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio 1Q Rev $22.9M >TSVT

2025. g. 7. maijs 20:08 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio 1Q EPS 1c >TSVT

2025. g. 7. maijs 20:08 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

2025. g. 7. maijs 20:07 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

2025. g. 29. apr. 19:47 UTC

Peļņas

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

2025. g. 29. apr. 15:22 UTC

Peļņas

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

2025. g. 29. apr. 11:46 UTC

Peļņas

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

2025. g. 29. apr. 11:42 UTC

Peļņas

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

2025. g. 29. apr. 11:12 UTC

Peļņas

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

2025. g. 28. apr. 21:15 UTC

Peļņas

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 14:15 UTC

Top Ziņas
Peļņas

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 12:37 UTC

Tirgus saruna
Peļņas

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

2025. g. 24. apr. 11:17 UTC

Peļņas

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

2025. g. 24. apr. 11:13 UTC

Top Ziņas
Peļņas

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

2025. g. 24. apr. 10:59 UTC

Peļņas

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Salīdzinājums

Cenas izmaiņa

Bristol-Myers Squibb Co. Prognoze

Cenas mērķis

By TipRanks

16.05% augšup

Prognoze 12 mēnešiem

Vidējais 55.53 USD  16.05%

Augstākais 68 USD

Zemākais 36 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bristol-Myers Squibb Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

20 ratings

5

Pirkt

14

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 50.57Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.